Kornimate/medical-research-clean huggingface dataset:
pancreatic endotherapy for refractory chronic pancreatitis

Conditions: Pancreatic Duct Stone; Pancreatic Duct Stricture; Pancreatic Duct Dilatation

Summary: the purpose of this study is to evaluate whether endoscopic ultrasound (eus) only versus eus + endoscopic retrograde cholangiopancreatography (ercp) with pancreatic endotherapy reduces pain in the treatment of chronic pancreatitis with pancreatic duct obstruction.

this is a single center, pilot, sham-controlled clinical trial of ercp with pancreatic endotherapy for pain secondary to chronic calcific pancreatitis with main pancreatic duct obstruction. potential subjects will undergo a comprehensive baseline assessment including quantitative sensory testing, to ensure enrollment criteria are met and baseline covariates are measured. eligible subjects will complete a 14-day run-in period. if eligibility criteria persist, subjects will be randomized to diagnostic endoscopic ultrasound (eus) + sham pancreatic endotherapy or diagnostic eus + ercp with pancreatic endotherapy as defined in the study protocol. subjects will be followed by a blinded physician for the next 90 days, at which time the pilot trial outcomes will be measured. regardless of outcomes, all subjects will be followed longitudinally for 12 months after randomization.

Eligibility criteria:
inclusion criteria * age ≥ 18 years * main pancreatic duct obstruction, defined by the presence of one or both of the following features: * main pancreatic duct calcification with upstream main duct dilation ≥6mm. * main pancreatic duct stricture, defined by the presence of main pancreatic duct narrowing with upstream main duct dilation ≥6mm. * baseline average abdominal pain score ≥4 during the run-in period, based on ecological momentary assessment 11-point numeric rating scale * ability to provide written, informed consent exclusion criteria * symptoms attributable to a pancreatic pseudocyst or walled off necrosis * clinical suspicion of pancreatobiliary malignancy\* * low probability of follow-up to complete study objectives * pregnancy or incarceration * medical comorbidities that contraindicate the performance of ercp * previous pancreatic endotherapy * current opioid misuse measure score ≥9 * does not have access to a mobile phone \* pancreatobiliary malignancy

Keywords: pancreas pancreatic duct ductal stone duct stricture ercp pancreatic duct obstruction duct calcification
the study of polycystic ovary syndrome (pcos) and questionnaire

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome (pcos) is an extremely common disorder in women of reproductive age. diagnosis of pcos is principally based on clinical and physical findings. diagnostic criteria and pcos definitions used by clinicians and researchers are almost as heterogeneous as the syndrome. this first part of study is determine whether genetic polymorphisms influence hormonal and metabolic characteristics in taiwanese patients with pcos and controls. furthermore, women with pcos were reported with high risk of cardiovascular disease, the investigators planned to calculate the difference of carotid intima-media thickness (imt) and b-type natriuretic peptide (bnp) between women with pcos and normal control to determine the premature atherosclerosis of women with pcos.


Eligibility criteria:
inclusion criteria: * women at reproductive age * women with pcos and women without pcos exclusion criteria: * young women who had their menarche less than 3 years * women older than 45 years old, amenorrhea of menopause, hyperglycemia, hyperthyroidism, hypothyroidism, heart failure, lung failure, renal failure, anemia, dystrophy, gonitis
comparaison of esp block and tap block

Conditions: Post Operative Pain

Summary: this study aim to compare the efficiency and the analgesic effect of erector spinal plane block versus tap block after laparoscopic cholecystectomy.

this study will include patients scheduled for laparoscopic cholecystectomy, asa status 1 or 2. patients will be randomized in 2 groups to recieve post operative analgesia with -esp block: bilateral injection of 20 ml of isobaric bupivacain 0,375% in the paraverebral space t5. or -tap block: bilateral injection of 15 ml of isobaric bupivacain 0,5%

Eligibility criteria:
inclusion criteria: * adult patients * asa status i or ii * scheduled for laparoscopic cholecystectomy exclusion criteria: * laparotomy * unplanned icu admission

Keywords: laparoscopic cholecystectomy post operative analgesia
sipuleucel-t and ipilimumab for advanced prostate cancer

Conditions: Prostate Cancer; Castrate Resistant Prostate Cancer

Summary: this is a clinical trial designed to quantify the immune response and determine the tolerability and side effects of sipuleucel-t when given in combination with ipilimumab for patients with advanced prostate cancer.


Eligibility criteria:
inclusion criteria: * subjects with advanced prostate cancer who are eligible to receive sipuleucel-t in accordance with fda approved labeling of sipuleucel-t * subjects must understand and sign an informed consent form exclusion criteria: * subjects who are not eligible to receive sipuleucel-t
oral nilotinib in adults with chronic myeloid leukemia (cml) in blast crisis who are imatinib resistant or intolerant

Conditions: Chronic Myelogenous Leukemia

Summary: this study will evaluate the safety of nilotinib in adult patients with imatinib-resistant or -intolerant cml-blast crisis, cml-accelerated phase or cml-chronic phase when treated with nilotinib. patients will be provided access to nilotinib until the drug is available on the market.


Eligibility criteria:
inclusion criteria: * imatinib resistant or intolerant philadelphia chromosome positive cml in blast crisis * imatinib resistant or intolerant philadelphia chromosome positive cml in accelerated phase * imatinib resistant or intolerant philadelphia chromosome positive cml in chronic phase * cml patients who have been treated with an investigational tyrosine kinase inhibitor who otherwise meet the definition of imatinib resistance or intolerance * world health organization (who) performance status ≤ 2 exclusion criteria: * cytopathologically confirmed central nervous system (cns) infiltration * impaired cardiac function * use of therapeutic coumarin derivatives * acute chronic liver or renal disease unrelated to tumor * other uncontrolled medical conditions * treatment with hematopoeitic colony stimulating factors * treatment with medications that have potential to prolong the qt interval * another malignancy currently clinically significant or requires active intervention other protocol-defined inclusion/exclusion criteria may apply.

Keywords: imatinib resistant, imatinib intolerant, cml- blast crisis, cml- accelerated phase, cml- chronic phase, nilotinib, chronic myelogenous leukemia, blast crisis, accelerated phase, chronic phase
outpatient antibiotic treatment for a cystic fibrosis pulmonary exacerbation

Conditions: Cystic Fibrosis

Summary: this study plans to learn more about the effect of oral antibiotics for an outpatient pulmonary exacerbation (respiratory illness) on sputum (mucus) bacterial infections, lung function, airway inflammation and quality of life. in this study subjects will perform pulmonary function tests, provide a sputum sample and complete a questionnaire at two separate clinic visits. if a subject is unable to cough up sputum in clinic he or she will be asked to breathe in a salt water solution to help cough up sputum. the first sputum sample will be obtained at the first visit (within 48 hours of starting antibiotics). pulmonary function testing and the questionnaire will also be completed at this time. subjects will complete a two week course of oral antibiotics at home. during these two weeks subjects will be asked to write down the times antibiotics are taken and airway clearance (vest treatment) is performed. within one week of completing the antibiotic course subjects will return to clinic for a second visit. at that time a sputum sample will be obtained again and if subjects are unable to cough up sputum they will again be asked to breathe in salt water solution to help cough up sputum. pulmonary function testing and the questionnaire will also be completed at this second visit. sputum samples will be tested for infections with bacteria and viruses. sputum samples will also be used to measure markers of airway inflammation (swelling). the investigators hypothesize that the use of two weeks of oral antibiotics for the treatment of a pulmonary exacerbation will result in a decrease in the amount of bacteria measured in sputum. additionally the investigators hypothesize that treatment with antibiotics will lead to an improvement in lung function, a decrease in airway inflammation and an improvement in quality of life measurements.


Eligibility criteria:
inclusion criteria: * diagnosis of cystic fibrosis based on sweat chloride (≥60) or two known disease causing mutations. * age 8 - 18 years * starting treatment for an outpatient pulmonary exacerbation * willing to participate in study after informed consent and assent has been obtained. exclusion criteria: * forced expiratory volume in 1 second (fev1) less than 40% * patients receiving chronic daily oral antibiotics. patients receiving azithromycin therapy three times a week will not be excluded as its use in this setting is felt to be anti-inflammatory. * previous reaction to inhalation of hypertonic saline. this is distinctly unusual in cystic fibrosis. * patients who have been treated with oral antibiotics on an outpatient basis within 2 weeks of the exacerbation. * patients who are being started simultaneously on inhaled and oral antibiotics. patients who are routinely receiving inhaled antibiotics as part of their chronic management and continue inhaled antibiotics as previously scheduled will not be excluded.
inflammation in tinnitus

Conditions: Tinnitus, Subjective; Tinnitus; Inflammation

Summary: rationale: tinnitus is the perception of sound without an external source. in the past decade, inflammation has been implicated in the pathophysiology of tinnitus. in animal models of tinnitus, the expression of proinflammatory cytokines tumor necrosis factor-α (tnf-α) and interleukine-1β (il-1β) was increased throughout the whole auditory tract. only two studies evaluated cytokine concentrations in tinnitus patients. in these studies an increase of il-6 and decrease of il-10 have been objectified. however, studies did not include tinnitus patients based on the degree of hearing loss, despite that inflammation has also been implicated in hearing loss. on the other hand, studies about inflammation in hearing loss did not (always) exclude tinnitus. thus, it remains unclear whether the upregulated cytokine concentrations the studies are specific for tinnitus, and whether potential effects remained unsignificant because the presence of hearing loss is a confounder. therefore, the aim of this study is to evaluate the presence of inflammation in tinnitus patients with normal hearing. objective: the main objective is to evaluate the presence of inflammation in blood samples of human subjects with tinnitus and normal hearing, compared to healthy controls. the secondary objective is to evaluate the relation between tinnitus severity and inflammatory marker concentrations. study design: this is a cross-sectional study. study population: patients who have been referred to the tinnitus consultation at the outpatient clinic will be asked to participate in this study. for the control group, healthy volunteers will be recruited. main study parameters/endpoints: the main study parameter is the disparity in blood cytokine levels between participants with and without tinnitus. secondary study parameters are the relation between tinnitus severity and blood cytokine concentration, and the difference in complete blood count measures in participants with and without tinnitus.


Eligibility criteria:
inclusion criteria: * to be eligible to participate in this study, a subject must meet all of the following criteria: * adult, aged 18 years or older; * hearing threshold: average of 1000khz, 2000khz \& 4000khz ≤ 25 db. * anxiety score hads ≤ 7 * depression score hads ≤ 7 * participant has sufficient mastery of the dutch language to fill out the questionnaires. * psychosocially, mentally, and physically able to fully comply with this protocol. exclusion criteria: * objective tinnitus. * presence of neurological disease (apart from tinnitus) * presence of inflammatory disease, or the use of anti-inflammatory medication. * presence or history of a malignancy * presence of a disease of the ear (e.g. chronic otitis media, otosclerosis, previous surgery etc). * presence of an coagulation disorder * presence of a serious psychiatric disorder. * pregnancy
acupuncture for patients with function dyspepsia

Conditions: Functional Dyspepsia; Postprandial Distress Syndrome

Summary: hypothesis: acupuncture is efficacious and safe for patients with functional dyspepsia design: * a single blind randomized controlled trial * 200 participants will be included * two arms: acupuncture and sham acupuncture group

aim: to clarify the efficacy and safety of acupuncture for patients with functional dyspepsia design: a single blind randomized controlled trial will be performed in chengdu, hunan and chongqing province. two hundred participants will be randomly assign to acupuncture and sham acupuncture group. each participants will receive 20 sessions of acupuncture in 4 weeks, with a duration of 30 minutes in a session. the primary outcome is patients' global assessments of efficacy in 16 weeks after inclusion. secondary outcomes include validated leeds dyspepsia questionnaire, nepean dyspepsia index, etc.

Eligibility criteria:
inclusion criteria: * consistent with the diagnostic criteria of functional dyspepsia. * age of a subject is older than 18 and is younger than 65.（including 18 and 65） * include postprandial distress syndrome. * did not take any gastroenteric dynamic drugs in the last 15 days, and did not take part in any clinical trial. * informed consent is signed by a subject or his lineal relation. exclusion criteria: * patients with any contraindications of itopride. * patients who are unconscious, psychotic. * patients with aggravating tumor and other serious consumptive disease, and who are subject to infection and bleeding. * with serious protopathy or disease of cardiovascular, liver, renal, gastrointestinal, hematological systems and so on. * pregnant women or women in lactation.

Keywords: functional dyspepsia postprandial distress syndrome
demographics, clinical and paraclinical characteristics of multiple sclerosis in egypt

Conditions: Multiple Sclerosis

Summary: the primary study aim is to depict the demographics, clinical and para clinical features of patients attending five tertiary referral multiple sclerosis (ms) centers in egypt. this requires effective and unified pooled registries to extract data from with a standardized, sufficient and high quality clinical, magnetic resonance imaging (mri) data, neurophysiological data and body fluids. investigators want to shed light on the challenges that face both physicians and patients in the area of "diagnosis and treatment"


Eligibility criteria:
inclusion criteria: * patients with ms/nmosd or their mimics who sought advice in one of our centers even once exclusion criteria: * patients with missing data in their records that couldn't be completed
patient care management strategies for severe heart failure in rhône-alpes, france.

Conditions: Severe Heart Failure

Summary: the heart failure is a chronic pathology with prevalence from 2 to 3% of general population, a death rate of 50% at 6 months for patients with stage iv, and a probability of death or hospitalization or emergency consultation of 40% at 3 years. the care of patients is heterogeneous, especially in light of the organization of therapeutic education offered to patients and patient monitoring modalities. the aim of this study is to investigate the management strategies for patients with chronic heart failure stage iii or iv nyha, and heart failure patients with stage ii nyha with previous hospitalization for heart failure. this is a longitudinal observational multicenter study comparing a management strategy including patient education and monitoring as part of a hospital dedicated organization and an organization of care as usually done in france. the primary endpoint was a composite endpoint of morbidity and mortality involving deaths, unplanned readmissions and emergency visits for heart failure. the expected number of patients is 720 patients (360 per strategy). the follow-up duration of 24 months.


Eligibility criteria:
inclusion criteria: * chronic heart failure patient with left ventricular ejection fraction (lvef) defined by an impaired lvef less than or equal to 40%. * heart failure stage iii or iv nyha, or heart failure patients with stage ii nyha with previous hospitalization for heart failure. * patient who has received a written or oral information of the study * patient affiliated with french health insurance exclusion criteria: * patient refusal to participate in the study * progressive neoplastic pathology. * patient with impaired cognitive functions known. * patient subject to a measure of socio-legal protection. * heart failure secondary to curable causes (an arrhythmia, valvular dysfunction, myocardial infarction, bypass surgery scheduled, aortic stenosis, breaking rope...) * dyspnea pulmonary origin: pulmonary arterial hypertension pre-capillary origin catheterization, defined by a pcap ≤15 mmhg. * patient who underwent ventricular mechanical assistance. * patient with acute breathlessness is explained by: a severe lung infection (cpt \<60% of predicted, ventricular ejection fraction \<60% predicted) or pulmonary embolism or respiratory failure with ambient air pao2 (arterial oxygen pressure) below 60 mmhg or oxygen therapy. * dialysis patient

Keywords: heart failure patient education as topic patient care management
doxycycline for helicobacter pylori rescue treatment

Conditions: Helicobacter Pylori Infection

Summary: current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy. however, tetracycline is clinically unavailable in china and the high frequency of adverse events of bismuth quadruple therapy often result in poor compliance, which limited the applicability of this recommendation. this study aimed to compare the efficacy and tolerability of a 14-day bismuth-containing quadruple rescue therapy in which tetracycline was replaced by doxycycline.


Eligibility criteria:
inclusion criteria: * ability and willingness to participate in the study and to sign and give informed consent * confirmed h. pylori infection and with previous treatment failure exclusion criteria: * subjects naive to h. pylori treatment, * under 18 or over 80 years old * history of gastrectomy * pregnant or lactating women * severe systemic diseases or malignancy * administration of antibiotics, bismuth, antisecretory drugs, or chinese herb medicine in the preceding 8 weeks

Keywords: helicobacter pylori rescue therapy doxycycline tetracycline
predictors of response to cognitive remediation in schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this study is to determine which variables predict improvement on a cognitive training task battery, used for patients with schizophrenia, and to determine the proportion of patients whose performance returns to normal following cognitive training

it has been suggested that level of cognitive function is a "rate-limiter" for the efficacy of other psychosocial treatments in schizophrenia. cognitive remediation, which entails training and practice of successively more difficult cognitive exercises, has shown efficacy in improving cognitive function. however, the rate of improvement has not been uniform among patients receiving this intervention. given the time- and cost-intensiveness of cognitive remediation, it is important to examine variables that will predict response to this treatment, as well as to examine the clinical significance of any improvement. the current proposal has two aims: 1) to determine which neuropsychological, demographic, and illness variables predict response to cognitive remediation training; and 2) to determine the proportion of patients whose performance returns to normal following cognitive remediation training. for the first part of the proposed study, 50 outpatients diagnosed with schizophrenia spectrum disorders will be invited to participate in an 8-week trial of cognitive remediation training. detailed neuropsychological, demographic, symptom and illness course variables will be collected prior to training, at the conclusion of training, and 4 months from study intake. in order to answer the second question, additional data on the computerized task performance for healthy controls will be collected, and compared to patient data, in order to determine what constitutes normal-range performance

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia spectrum disorder * english speakers * clinically stable * no substance abuse in past 30 days exclusion criteria: * traumatic brain injury * neurological disease * diagnosis of mental retardation

Keywords: cognition neuropsychology rehabilitation treatment efficacy cognitive remediation
the effects of omega-3 fatty acids supplementation on endothelial function and inflammation

Conditions: Peripheral Arterial Disease

Summary: the hypothesis being tested is that in patients with stable claudication and documented pad, omega-3 supplementation for 1 month will lead to improvement in endothelial function as measured by flow-mediated, brachial artery vasodilation (fmd), as well as improvement in the vascular inflammatory profile as measured by a panel of established circulating inflammatory biomarkers.


Eligibility criteria:
inclusion criteria: * intermittent claudication * resting or exercise ankle-brachial index (abi) \<0.9 * age 50 and more exclusion criteria: * critical limb ischemia * hypersensitivity/allergies to fish or seafood * already on omega-3 fatty acids or equivalent * significant renal, hepatic, and inflammatory disease * concurrent severe infections * acute illness (mi, stroke, major surgery within 30 days) * receiving immunosuppressive medications or steroids